Skip to content

Bolt Biotherapeutics, Inc.

BOLT

CIK 0001641281

← back to feed
Revenue (TTM)
$5.22M
+0.1% YoY Q1 May 2026
Net Income (TTM)
−$33.99M
+47.1% YoY Q1 May 2026
EPS Diluted (TTM)
−$18.25
+46.0% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-701.6%
Q1 May 2026
Net Margin
-651.0%
Q1 May 2026
Free Cash Flow (TTM)
−$62.2M
Q1 May 2026
Cash
$11.61M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
1.92M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings